Carbogen Amcis enters into a co-investment agreement of CHF 25+ million to expand Swiss sites
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
This project builds on a previous joint funding agreement between CARBOGEN AMCIS and the same customer in April 2021
Ingredion will have exclusive access to Amyris’ technology to manufacture and sell fermented Reb M
In Q4 FY25, our pharmaceutical business reported revenue growth of 20% to Rs 351 crore and EBIT growth of 65% to Rs 55 croe, on QoQ basis
For the full financial year FY25, revenue from operations grew 9 per cent to Rs. 11,537.8 crore, compared to Rs. 10,588 crore in FY24.
PAT stood at Rs. 88 crore for Q4 FY25 as compared to Rs. 56 crore in Q4FY24, an increase of 57%
Investment demonstrates confidence in America’s commitment to science and innovation
The company has received final approval from the Department of Pharmaceuticals, Government of India, for foreign investment under applicable regulations
The partnership provides Sai Life Sciences with a greenhouse gas emissions reduction of up to 90% for its international logistics needs by using SAF
Strengthening capabilities in Peptide Therapeutics and CDMO services
Subscribe To Our Newsletter & Stay Updated